Progress in developmental and stem cell biology is revolutionising drug discovery research; the ability to grow and differentiate stem cell lines is providing a far more relevant model for pre-clinical testing. So much so that the FDA is looking into replacing previous models as a matter of urgency. However, challenges in assay development, scale up and quality control still persist and need to be addressed in order for success in this field to continue.
Stem Cells in Drug Discovery 2017 will see an even larger event with more talks, attendees and discussions than ever before. Hear from and network with researchers who are currently screening for efficacy and toxicity using iPS cell lines, and those responsible for developing the techniques and technologies enabling them to do so. There will also be discussions on industry and regulatory developments that are shaping the future of drug discovery.
Registration includes unrestricted access to all conference tracks and a reception dinner at the end of the first day.